Lyme disease vaccination: safety first - author's reply.
作者信息
Lantos Paul M
机构信息
Duke University School of Medicine, DUMC 100800, Durham, NC 27710, USA.
出版信息
Lancet Infect Dis. 2014 Jan;14(1):13. doi: 10.1016/S1473-3099(13)70346-3.
Abstract
摘要
相似文献
1
Lyme disease vaccination: safety first - author's reply.
Lancet Infect Dis. 2014 Jan;14(1):13. doi: 10.1016/S1473-3099(13)70346-3.
2
Lyme disease vaccination: safety first - authors' reply.
Lancet Infect Dis. 2014 Jan;14(1):12-13. doi: 10.1016/S1473-3099(13)70362-1.
3
Lyme disease vaccination: safety first.
Lancet Infect Dis. 2014 Jan;14(1):12. doi: 10.1016/S1473-3099(13)70319-0.
4
Lyme disease vaccination: are we ready to try again?
Lancet Infect Dis. 2013 Aug;13(8):643-4. doi: 10.1016/S1473-3099(13)70085-9. Epub 2013 May 10.
5
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.
Lancet Infect Dis. 2013 Aug;13(8):680-9. doi: 10.1016/S1473-3099(13)70110-5. Epub 2013 May 10.
6
Safety, immunogenicity, and efficacy of Borrelia burgdorferi outer surface protein A (OspA) vaccine: A meta-analysis.
J Infect Dev Ctries. 2017 Jan 30;11(1):1-9. doi: 10.3855/jidc.7999.
7
Lyme vaccine demonized by advocacy groups.
Nature. 2006 Mar 16;440(7082):278. doi: 10.1038/440278b.
8
The need for a new vaccine against lyme borreliosis.
Expert Rev Vaccines. 2013 Feb;12(2):101-3. doi: 10.1586/erv.12.141.
9
Outer surface protein A and arthritis in hamsters.
Infect Immun. 2000 Dec;68(12):7212-3. doi: 10.1128/IAI.68.12.7212-7213.2000.
10
Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against lyme disease in healthy children and adolescents: a randomized controlled trial.
Pediatrics. 2001 Jul;108(1):123-8. doi: 10.1542/peds.108.1.123.
Zotero 插件